Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Neoplasms
Interventions: DRUG: VIP236
Sponsor: Vincerx Pharma, Inc.